



SOHO

CENTRAL EUROPE
BUDAPEST

2026

CENTRAL EUROPEAN MEETING OF THE SOCIETY OF HEMATOLOGIC ONCOLOGY

BUDAPEST, HUNGARY 2026



9–10 OCTOBER, 2026, BUDAPEST

Mercure Budapest Castle Hill (H-1013 Budapest, Krisztina körút 41–43.)

PROGRAMME



Central European SOHO Meeting 2026

Programme

October 9, Friday – MPN, AML, MDS, CLL & Lymphoma

09:30 – 11:10

SESSION I. – MPN & CML

CHAIR: *A. Hussain & J. Apperley*

09:30

Opening remarks

09:40

When the Guidelines don't Help!

Jane Apperley

HAMMERSMITH, UK

09:55

Why, when and in whom to stop CML treatment safely

Jiří Mayer

MASARYK UNIV. BRNO, CZ

10:10

Between Risk and Reality: The haemostatic problem in MPN

Alizadeh Hussain

UNIV. PÉCS, HU

10:25

Clinical scenarios: hemostatic challenges in MPN

Dražen Pulanić

UNIV. ZAGREB, HR

10:40 – 11:10

Discussion

11:10 – 12:55

SESSION II. – AML

CHAIR: *Árpád Bátaí & Naval Daver*

11:10

Ven-Aza – a rising star?

Peter Farkas

SEMMELWEIS UNIV, BUDAPEST, HU

11:25

Assessment of fitness and therapeutic options in unfit AML patients

Mirta Mikulić

UNIV. ZAGREB, HR

11:40

The role of HSCT for AML in first CR

Árpád Bátaí

SZT. LÁSZLÓ HOSP., HU



9-10 OCTOBER, 2026

BUDAPEST (Mercure Budapest Castle Hill)



SOHO
CENTRAL EUROPE
BUDAPEST

2026

Programme – October 9, Friday

11:55

Managing FLT3 mutant AML

Gabriel Ghiaur

HOPKINS/BUCHAREST, RO / USA

12:10

Management of AML in patients unfit for aggressive treatment

Matevž Škerget

MED. CENTER LJUBLJANA, SL

12:25 – 12:55

Discussion

13:20 – 14:20

PARALLEL LUNCH SYMPOSIA

ROOM A – ABBVIE LUNCH SYMPOSIUM

ROOM B – RECORDATI LUNCH SYMPOSIUM

14:20 – 16:05

SESSION III. – CLL

CHAIR: *Róbert Szász & Othman Al-Sawaf*

14:20

First-line continuous therapies

Othman Al-Sawaf

UNIV. COLOGNE, DE

14:35

First-line, fixed-duration therapies

Róbert Szász

UNIV. DEBRECEN, HU

14:50

Prophylaxis of infectious complications in CLL

Iwona Hus

UNIV. LUBLIN, PL

15:05

The Richter transformation; are there any changes in 2026?

Sandra Basic-Kinda

UNIV. ZAGREB, HR

15:20

Treatment of CLL in the near future

Michael Doubek

UNIV. HOSP. BRNO, CZ

15:35 – 16:05

Discussion

16:05 – 17:50

SESSION IV. – MDS

CHAIR: *Viktor Lakatos & Varun Mehra*

16:05

Updates in diagnostics/immunobiological understanding and impact of prognostic scoring in decision making

Varun Mehra

KINGS COLLEGE HOSP. LONDON, UK

16:20	Non-transplant treatment strategies of high-risk MDS <i>Inga Mandac-Smoljanović</i> MERKUR HOSP., ZAGREB, HR
16:35	Pre- and post-transplant strategies to improve outcomes of HSCT for MDS <i>Viktor Lakatos</i> ST. LÁSZLÓ HOSP., HU
16:50	HSCT in MDS, indications, outcomes, strategies <i>Alina Tanase</i> INSTIT. CLINIC FUNDENI, BUCHAREST, RO
17:05	Low-risk MDS therapy - advances in recent years <i>Anna Jonášová</i> CHARLES UNIV., PRAGUE, CZ
17:20 – 17:50	Discussion
17:50 – 18:10	COFFEE BREAK
18:10 – 19:55	SESSION V. – IND. NHL & MCL CHAIR: <i>A. Masszi & I. Aurer</i>
18:10	Treatment of HL in 2026 <i>Igor Aurer</i> UNIV. ZAGREB, HR
18:25	Frontline therapy of MCL <i>Wojciech Jurczak</i> NATIONAL RESEARCH INST. ONCOL, KRAKOW, PL
18:40	Frontline treatment of FL <i>András Masszi</i> ONCOL INST. BUDAPEST, HU
18:55	Treatment landscape of R/R FL in 2026 <i>Vít Procházka</i> UNIV. HOSP., OLOMOUC, CZ
19:10	Management of R/R MCL in 2026 <i>Pavel Klener</i> CHARLES UNIV., PRAGUE, CZ
19:25 – 19:55	Discussion
19:55 – 20:55	ASTELLAS EVENING SYMPOSIUM



9-10 OCTOBER, 2026

BUDAPEST (Mercure Budapest Castle Hill) (ar)



SOHO
CENTRAL EUROPE
BUDAPEST

2026

Programme – October 10, Saturday

October 10, Saturday – BM failure, PNH, ALL, Cellular therapy, MM, LBCL

08:00 – 09:30

SESSION VI BM FAILURE & PNH

CHAIR: *I. Bodó & M. Griffin*

08:00

Approach to classic PNH in 2026

Imre Bodó

SEMMELWEIS UNIV, BUDAPEST, HU

08:15

The failing bone marrow and PNH

Morag Griffin

ST. JAMES HOS. LEEDS, UK

08:30

Severe aplastic anemia in 2026

Phil Scheinberg

SAO JOSE HOSP, SAO PAULO, BR

08:45

HSCT for TBD-related BM failure Syndromes: Progress and challenges

Pál Szabolcs

UPMC CHILDREN'S HOSP. PITTSBURGH, USA

09:00 – 09:30

Discussion

09:30 – 11:50

SESSION VII. – ALL

CHAIR: *Zsolt Nagy & Nicola Gökbüget*

09:30

How to improve outcome of T-ALL

Nicola Gökbüget

UNIVERSITY OF FRANKFURT, DE

09:45

Evolving paradigms of the treatment of adults with B-cell Ph- ALL

Sebastian Giebel

GLIWICE, PL

10:00

Ph+ ALL in 2026

Zsolt Nagy

SEMMELWEIS UNIV, BUDAPEST, HU

10:15

SupporAve care in ALL

Zinaida Perić

CLINICAL HOSP.CTR, RIJEKA, HR

10:30 – 11:50

Discussion

11:50 – 12:50

PARALLEL LUNCH SYMPOSIA

ROOM A – SOBI LUNCH SYMPOSIUM

ROOM B – PFIZER LUNCH SYMPOSIUM

12:50 – 14:35

SESSION VIII. – CELLULAR THER.

CHAIR: *P. Reményi & J. DiPersio*

12:50

Can AML and T-ALL be effectively treated with CAR-T?

John DiPersio

WASHINGTON UNIV. STL, MO, US

13:05

Virus-specific T-cell therapies

Krisztián Kállay

SZT. LÁSZLÓ HOSP, BUDAPEST, HU

13:20

Role of cellular therapies in the management of MCL

Ciprian Tomuleasa

CHIRICUTA CANCER CTR, CLUJ, RO

13:35

Infectious complications after CAR-T cell therapy

Lidia Gil

MEDICAL UNIV, POZNAN PL

13:50

Academic/Point of Care CAR-T Cell Therapies – Focus on Europe

Matjaž Sever

MED. CENTER LJUBLJANA, SL

14:05 – 14:35

Discussion

14:35 – 16:05

SESSION IX. – MM

CHAIR: *Gergely Varga & Gábor Mikala*

14:35

Current praxis: focus on engaging T-cells (bispecifics and CAR)

Roman Hájek

UNIV. HOSPITAL OSTRAVA, CZ

14:50

Down with Dex!

Gergely Varga

SEMMELWEIS UNIV., HU

15:05

Supportive care in multiple myeloma

Artur Jurczyszyn

JAGELLONIAN UNIV., PL

15:20

Small molecules in the Era of immune therapies

Gábor Mikala

SEMMELWEIS UNIV., HU



9-10 OCTOBER, 2026

BUDAPEST (Mercure Budapest Castle Hill) (ar)



SOHO
CENTRAL EUROPE
BUDAPEST

2026

Programme – October 10, Saturday

15:35 – 16:05

Discussion

16:05 – 16:25

COFFEE BREAK

16:25 – 17:55

SESSION X. – LBCL

CHAIR: *Gergely Lajos & Marek Trněný*

16:25

First line DLBCL Therapy: Choosing Wisely

Marek Trněný

CHARLES UNIV, PRAGUE, CZ

16:40

Are we ready for MRD in DLBCL?

Gergely Lajos

UNIV. DEBRECEN, HU

16:55

Management of R/R LBCL: the future is now

Ľuboš Drgoňa

COMENIUS UNIV, BRATISLAVA, SK

17:10

The role of bispecific antibodies in aggressive LBCL

Monika Długosz-Danecka

KRAKOW, PL

17:25 – 17:55

Discussion

17:55

CLOSING REMARKS



SOHO
CENTRAL EUROPE
BUDAPEST

2026



“Régio-10” Kft.

Address: H-6722 Szeged,
Szentháromság utca 19.

Phone: +36 62 710 500

Mobile: +36 20 446 9244

E-mail: info@regio10.hu

Web: www.regio10.hu